Pharma Equity Group A/S Cl A Cash Flow Conversion Efficiency
Pharma Equity Group A/S Cl A cash flow conversion efficiency. Based on the latest financial reports, Pharma Equity Group A/S Cl A (PEG) has a cash flow conversion efficiency ratio of -0.136x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr-6.66 Million ≈ $-1.04 Million USD) by net assets (Dkr48.88 Million ≈ $7.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pharma Equity Group A/S Cl A (2009–2025)
Cash flow conversion efficiency of Pharma Equity Group A/S Cl A from 2009 to 2025. This chart illustrates how Pharma Equity Group A/S Cl A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Pharma Equity Group A/S Cl A stock quote for real-time trading data and today's change.
Pharma Equity Group A/S Cl A Cash Flow Conversion Ratio Explained
Pharma Equity Group A/S Cl A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pharma Equity Group A/S Cl A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharma Equity Group A/S Cl A ranked by their cash flow conversion efficiency. Also see market value of Pharma Equity Group A/S Cl A for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KR Motors Co. Ltd.
KO:000040
|
0.032x |
|
Vinpai SAS
PA:ALVIN
|
-0.313x |
|
IDT Australia Ltd
AU:IDT
|
-0.047x |
|
FIPP S.A.
PA:FIPP
|
0.002x |
|
Foxx Development Holdings Inc.
NASDAQ:FOXX
|
-0.030x |
|
Aguia Resources Ltd
AU:AGR
|
-0.050x |
|
Pegasus Heights Bhd
KLSE:4464
|
0.018x |
|
Excel Realty N Infra Limited
NSE:EXCEL
|
3.473x |
Annual Cash Flow Conversion Efficiency for Pharma Equity Group A/S Cl A (2009–2025)
The table below shows the annual cash flow conversion efficiency of Pharma Equity Group A/S Cl A from 2009 to 2025. Review Pharma Equity Group A/S Cl A (PEG) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | Dkr25.47 Million ≈ $3.99 Million |
Dkr-17.66 Million ≈ $-2.76 Million |
-0.693x | -48.23% |
| 2024-09-30 | Dkr48.88 Million ≈ $7.65 Million |
Dkr-22.86 Million ≈ $-3.58 Million |
-0.468x | +28.72% |
| 2023-09-30 | Dkr25.33 Million ≈ $3.96 Million |
Dkr-16.62 Million ≈ $-2.60 Million |
-0.656x | -951.34% |
| 2022-09-30 | Dkr46.05 Million ≈ $7.20 Million |
Dkr-2.87 Million ≈ $-449.66K |
-0.062x | -27.18% |
| 2021-09-30 | Dkr42.57 Million ≈ $6.66 Million |
Dkr-2.09 Million ≈ $-326.84K |
-0.049x | +83.01% |
| 2020-09-30 | Dkr34.28 Million ≈ $5.36 Million |
Dkr-9.90 Million ≈ $-1.55 Million |
-0.289x | -6981.66% |
| 2019-09-30 | Dkr67.16 Million ≈ $10.51 Million |
Dkr-274.00K ≈ $-42.87K |
-0.004x | +79.96% |
| 2018-09-30 | Dkr77.57 Million ≈ $12.14 Million |
Dkr-1.58 Million ≈ $-247.05K |
-0.020x | +64.80% |
| 2017-09-30 | Dkr85.09 Million ≈ $13.31 Million |
Dkr-4.92 Million ≈ $-769.93K |
-0.058x | -2992.17% |
| 2016-09-30 | Dkr96.78 Million ≈ $15.14 Million |
Dkr-181.00K ≈ $-28.32K |
-0.002x | +93.66% |
| 2015-09-30 | Dkr99.53 Million ≈ $15.57 Million |
Dkr-2.94 Million ≈ $-459.67K |
-0.030x | +39.77% |
| 2014-09-30 | Dkr97.95 Million ≈ $15.32 Million |
Dkr-4.80 Million ≈ $-750.99K |
-0.049x | -189.26% |
| 2013-09-30 | Dkr-105.44 Million ≈ $-16.50 Million |
Dkr-5.79 Million ≈ $-905.73K |
0.055x | +118.92% |
| 2012-09-30 | Dkr36.39 Million ≈ $5.69 Million |
Dkr-10.56 Million ≈ $-1.65 Million |
-0.290x | -304.66% |
| 2011-09-30 | Dkr79.67 Million ≈ $12.46 Million |
Dkr-5.71 Million ≈ $-893.84K |
-0.072x | +78.56% |
| 2010-09-30 | Dkr53.06 Million ≈ $8.30 Million |
Dkr-17.75 Million ≈ $-2.78 Million |
-0.334x | -2303.51% |
| 2009-09-30 | Dkr53.47 Million ≈ $8.37 Million |
Dkr-744.00K ≈ $-116.40K |
-0.014x | -- |
About Pharma Equity Group A/S Cl A
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment… Read more